Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized poractant alfa before methacholine challenge in asthma
ACTRN12605000790640Phase 3Withdrawn
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Poractant alfa in asthma (2 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoint: Fall in forced expiratory volume in one second. Planned start Feb 2006; status: withdrawn.
02
Drugs
Poractant alfa
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12605000790640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000790640.